| Objective: At present, paclitaxel(PTX) is chosen as one of the first-line drugs for ovarian caner. And the combination of platinum and paclitaxel is considered to be the standard therapy scheme for progressed ovarian caner. Despite improvements in progression-free survival and overall survival, the problems of relapsing and drug-resisting are still serious and long-term survival rates for patients with advanced epithelial ovarian carcinoma(EOC) remain disappointing. The current most evaluated modification of standard therapy is the addition of a third non-cross-resistant drug to platinum and paclitaxel. Etoposide(VP-16), as one of topoisomeraseII inhibitors, is among these drugs. The response rate is 25% when etoposide is used alone as second-line drug for ovarian cancer. This study was carried out to explore the different effects of paclitaxel/ cisplatin combination and paclitaxel/cisplatin/etoposide combination on inhibiting SKOV3 ovarian cancer cells. We hope that might be helpful for selecting efficiency drugs for ovarian cancer. Paclitaxel, in addition to having an effect on microtubules, may also induce cell apoptosis, which is not known clearly. Cell apoptosis is in connection with specific...
|
PDF Full Text Request